$0.46 3.6%
XFOR Stock Price vs. AI Score
Data gathered: January 29

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - X4 Pharmaceuticals (XFOR)

Analysis generated January 27, 2025. Powered by Chat GPT.

X4 Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company's primary area of expertise lies in immuno-oncology, chronic diseases, and genetic disorders. The firm has been active in clinical research, aiming to bring innovative treatments to market. Despite the potential within the pharmaceutical industry, X4 Pharmaceuticals faces the challenges of high research and development costs, long drug development timelines, and the competitive nature of the sector.

Read full AI stock Analysis

Stock Alerts - X4 Pharmaceuticals (XFOR)

company logo X4 Pharmaceuticals | January 28
Insider Alert: Ragan Paula is selling shares
company logo X4 Pharmaceuticals | January 27
Price is down by -5.8% in the last 24h.
company logo X4 Pharmaceuticals | January 24
Price is down by -5.4% in the last 24h.
company logo X4 Pharmaceuticals | January 23
Price is up by 6.4% in the last 24h.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.


X4 Pharmaceuticals
Price $0.46
Target Price Sign up
Volume 418,190
Market Cap $84M
Year Range $0.28 - $1.11
Dividend Yield 0%
PE Ratio 2.85
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24560,000230,000330,000-37M-34M-0.180
Q2 '24560,000270,000300,00091M93M-0.070
Q1 '2400-19M-52M-50M-0.260
Q4 '2324M9.9M-12M-19M-17M-0.100
Q3 '2300-9.7M-2.3M-26M-0.010

Insider Transactions View All

Arbet-Engels Christophe filed to sell 14,207 shares at $0.5.
January 27 '25
DiBiase Mary filed to sell 490,980 shares at $0.5.
January 27 '25
Baldry Mark filed to sell 94,123 shares at $0.5.
January 27 '25
Ragan Paula filed to sell 1,087,386 shares at $0.5.
January 27 '25

What is the Market Cap of X4 Pharmaceuticals?

The Market Cap of X4 Pharmaceuticals is $84M.

What is X4 Pharmaceuticals' PE Ratio?

As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 2.85.

What is the current stock price of X4 Pharmaceuticals?

Currently, the price of one share of X4 Pharmaceuticals stock is $0.46.

How can I analyze the XFOR stock price chart for investment decisions?

The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.

Does XFOR offer dividends to its shareholders?

As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of X4 Pharmaceuticals?

Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.